e-Therapeutics PLC | Ownership
Companies that own e-Therapeutics PLC
Invesco Asset Management Ltd.
84,524,060
31.47%
0
0.01%
03/22/2018
Woodford Investment Management Ltd.
46,807,479
17.43%
0
0.04%
03/22/2018
Lombard Odier Asset Management (Europe) Ltd.
32,142,027
11.97%
0
0.07%
03/22/2018
Octopus Investments Ltd.
11,097,658
4.13%
0
0.05%
03/22/2018
NFU Mutual Investment Services Ltd.
6,662,000
2.48%
0
0.01%
07/01/2018
Henderson Global Investors Ltd.
5,408,011
2%
0
0%
07/01/2018
HSBC Bank Plc (Market-Maker)
2,694,000
1%
0
0.05%
07/01/2018
Hargreaves Lansdown Asset Management Ltd.
1,450,000
0.54%
278,000
0%
07/01/2018
Hargreaves Lansdown Stockbrokers Ltd.
1,224,000
0.46%
76,000
0%
07/01/2018
Royal Bank of Canada (Channel Islands) Ltd.
776,000
0.28%
0
0%
07/01/2018
| Address |
17 Blenheim Office Park
Long Hanborough Oxfordshire OX29 8LN
United Kingdom
|
|
Employees
|
- |
| Website |
http://etherapeutics.co.uk |
| Updated |
07/08/2019 |
| e-Therapeutics Plc is a drug discovery and development company, which engages in the provision of evaluation services to investors and pharmaceutical companies. It focuses on the therapeutic immune-oncology, addressing drug resistance in targeted cancer therapies and antivirals. It offers the following variety of preclinical stage assets: ETS2300, telomerase inhibition in anti-cancer; ETS3100, small molecule anti-TNFa; ETS2400, Hedgehog pathway inhibition; and ETS5200, broad spectrum antivirals together with two immuno-oncology checkpoint projects. |
